AbbVie Inc. (ETR:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 350.31B |
| Revenue (ttm) | 49.67B |
| Net Income (ttm) | 3.17B |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 110.50 |
| Forward PE | 19.59 |
| Dividend | 5.86 (2.91%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 67 |
| Average Volume | 538 |
| Open | 199.60 |
| Previous Close | 201.00 |
| Day's Range | 199.60 - 202.00 |
| 52-Week Range | 147.60 - 207.00 |
| Beta | 0.51 |
| RSI | 66.32 |
| Earnings Date | Oct 29, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Piper Sandler Raises Price Target for AbbVie (ABBV) to $284, Maintains Overweight Rating | ABBV ...
Piper Sandler Raises Price Target for AbbVie (ABBV) to $284, Maintains Overweight Rating | ABBV Stock News
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Carolina Wealth Trims It's AbbVie Stake to Nearly Nothing
See Which Of The Latest 13F Filers Holds ABBV
At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 09/30/2025 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 12 of these funds. ...
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA5® moisturizer is design...
How pharma giant AbbVie holds leaders accountable for culture
The pharmaceutical company is one of the honorees on the Fortune 100 Best Companies to Work For Europe list in 2025.
A Congress Member Sold Up To $300K In A.O. Smith Stock: Here's What You Need To Know
A October filing shows that Representative Julie Johnson reported a sale in A.O. Smith (NYSE: AOS), valued between $20,020 and $300,000. The transaction date is listed as September 25, 2025, with the...
Why AbbVie Stock Soared in September
Key PointsAbbVie notched a huge win when it managed to extend patent exclusivity for a blockbuster drug.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
AbbVie's (ABBV) Botox Study Shows Promising Results for Essential Tremor
AbbVie's (ABBV) Botox Study Shows Promising Results for Essential Tremor
Noteworthy ETF Inflows: VOO, JNJ, HD, ABBV
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approxima...
AbbVie's Botox Shows Improvement In Movement Disorder Study
AbbVie Inc. (NYSE: ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor . Upper limb essential...
AbbVie (ABBV) Achieves Positive Results in Phase 2 Trial for Essential Tremor
AbbVie (ABBV) Achieves Positive Results in Phase 2 Trial for Essential Tremor
AbbVie (ABBV) Positioned Amid Gilead's Patent Extension for Biktarvy
AbbVie (ABBV) Positioned Amid Gilead's Patent Extension for Biktarvy
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
AbbVie succeeds in mid-stage study of neurological disease treatment
AbbVie Says Phase 2 ELATE Trial Met Primary Endpoint For BOTOX To Treat Upper Limb Essential Tremor
(RTTNews) - AbbVie, Inc. (ABBV) announced Monday positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX) compared to placebo for the trea...
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total un...
Top Dividend Stocks Poised for Explosive Growth in 2026 (ABBV, GD, RGR)
Geopolitical events, judicial rulings, new law legislation, and policy changes are all circumstances occurring on domestic and international stages that are triggering big stock moves in various indus...
National Medical Commission still to act on junketeering doctors
The National Medical Commission (NMC) has yet to act against 30 doctors found guilty of accepting a foreign trip funded by pharma company AbbVie. This delay stems from four out of five vacant posts in...
AbbVie (ABBV) Projects Lower Q3 Earnings Due to IPR&D Costs
AbbVie (ABBV) Projects Lower Q3 Earnings Due to IPR&D Costs
ABBV Surpasses Earnings Expectations with Strong Q3 Performance
ABBV Surpasses Earnings Expectations with Strong Q3 Performance
AbbVie (ABBV) Anticipates Financial Impact from Third Quarter Expenses
AbbVie (ABBV) Anticipates Financial Impact from Third Quarter Expenses